L 659699
Alternative Names: 1233A; F 244Latest Information Update: 15 Feb 1995
At a glance
- Originator Merck & Co
- Class Antihyperlipidaemics
- Mechanism of Action Cholesterol synthesis inhibitors; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 15 Feb 1995 Discontinued-Preclinical for Hypercholesterolaemia in USA (Unknown route)